WB, IF-IC, FC-FP
H M R
Endogenous
14, 16
Rabbit IgG
#Q9H0R8
23710
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunofluorescence (Immunocytochemistry) | 1:200 |
| Flow Cytometry (Fixed/Permeabilized) | 1:100 |
Storage
For a carrier free (BSA and azide free) version of this product see product #37737.
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human GABARAPL1 protein.
Background
GABAA receptor associated protein (GABARAP) is an Atg8 family protein with a key role in autophagy, which was originally discovered as a protein associated with the GABAA receptor regulating receptor trafficking to the plasma membrane (1). Proteins in this family, including microtubule-associated protein light chain 3 (LC3) and GATE-16 (GABARAPL2), become incorporated into the autophagosomal membranes following autophagic stimuli such as starvation (2). Like the other family members, GABARAP is cleaved at its carboxyl terminus, which leads to conjugation by either of the phospholipids phosphatidylethanolamine or phosphatidylserine (3,4). This processing converts GABARAP from a type I to a type II membrane bound form involved in autophagosome biogenesis. Processing of GABARAP involves cleavage by Atg4 family members (5,6) followed by conjugation by the E1 and E2 like enzymes Atg7 and Atg3 (7,8). GABARAPL1/GEC1, a protein that is highly related to GABARAP, was identified as an estrogen inducible gene, and is also associated with autophagosomes (9-11).
Gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1) appears to be more highly expressed in the CNS as compared to other family members (12-14). Expression of GABARAPL1 is associated with prognosis of some cancers, including hepatocellular and breast cancer (15,16). Inhibition of GABARAPL1 expression in breast cancer cells attenuates autophagic flux, results in metabolic changes, and leads to cancer promoting activities (17).
- Wang, H. et al. (1999) Nature 397, 69-72.
- Shpilka, T. et al. (2011) Genome Biol 12, 226.
- Kabeya, Y. et al. (2004) J Cell Sci 117, 2805-12.
- Sou, Y.S. et al. (2006) J Biol Chem 281, 3017-24.
- Tanida, I. et al. (2004) J Biol Chem 279, 36268-76.
- Hemelaar, J. et al. (2003) J Biol Chem 278, 51841-50.
- Tanida, I. et al. (2001) J Biol Chem 276, 1701-6.
- Tanida, I. et al. (2002) J Biol Chem 277, 13739-44.
- Chakrama, F.Z. et al. (2010) Autophagy 6, 495-505.
- Pellerin, I. et al. (1993) Mol Cell Endocrinol 90, R17-21.
- Vernier-Magnin, S. et al. (2001) Biochem Biophys Res Commun 284, 118-25.
- Nemos, C. et al. (2003) Brain Res Mol Brain Res 119, 216-9.
- Wang, Y. et al. (2006) Neuroscience 140, 1265-76.
- Le Grand, J.N. et al. (2013) PLoS One 8, e63133.
- Liu, C. et al. (2014) Oncol Rep 31, 2043-8.
- Berthier, A. et al. (2010) Br J Cancer 102, 1024-31.
- Boyer-Guittaut, M. et al. (2014) Autophagy 10, 986-1003.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
